结论雷米普利对治疗血液透析患者高血压有效。
CONCLUSION the effect of ramipril therapy on hypertension patients with hemodialysis is significance.
目的探讨动态血压监测指导腹膜透析患者高血压治疗的意义。
Objective to investigate the effect of hypertension treatment for peritoneal dialysis patients assessed and guided by dynamic blood pressure (BP) monitoring.
血液透析组出现低血压、高血压、心绞痛等不良反应，有22例次低血压患者经对症治疗无效，需终止治疗。
As for those with hemodialysis, such adverse reactions as hypertension, hypotension, angina pectoris occurred. 22 cases of hypotension quitted from treatment due to ineffective treatment.
结论：对腹膜透析患者实行长期的容量管理，可有效降低患者高血压的发生率。
The patient 's condition was improved obviously. Conclusion: Long-term control of volume capacity for patients with peritoneal dialysis can effectively reduce the incidence of hypertension.
这似乎是一个行之有效但是容易被透析的高血压患者忽略的措施。
This appears to be an effective but forgotten strategy in controlling and maintaining blood pressure control among hypertensive patients on dialysis.
结果非透析CRF患者的心血管并发症的总发病率为41.51%，其中慢性肾小球肾炎CRF、高血压肾病CRF、糖尿病肾病CRF并发心血管疾病的比例分别为26.62%、6.92%和5.45%；
Results The total incidence was 41.51% in non-dialysis CRF patients, 26.62%, 6.92% and 5.45% in glomerulonephritis CRF, hypertensive CRF and diabetic CRF respectively;
结果非透析CRF患者的心血管并发症的总发病率为41.51%，其中慢性肾小球肾炎CRF、高血压肾病CRF、糖尿病肾病CRF并发心血管疾病的比例分别为26.62%、6.92%和5.45%；
Results The total incidence was 41.51% in non-dialysis CRF patients, 26.62%, 6.92% and 5.45% in glomerulonephritis CRF, hypertensive CRF and diabetic CRF respectively;
应用推荐